The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|April 1, 2013
- Applied Clinical Trials-04-01-2013
- Volume 22
- Issue 4
Applied Clinical Trials Digital Edition April 2013
CRO/Sponsor: Strategic Partnerships in Trial Outsourcing Trial Design: The Future of Clinical Monitoring Project Management: Negotiating Effective Agreements and Budgets Also in this issue: Trial Debate in European Parliament Redefining Key Roles Biospecimen Storage
Advertisement
Articles in this issue
over 13 years ago
Act coverover 13 years ago
FDA Promotes Quality and Risk Managementover 13 years ago
Personalized Medicineover 13 years ago
Collaboration Planningover 13 years ago
Standardization in Biospecimen Storage and Researchover 13 years ago
Business and People April 2013over 13 years ago
Act Insert Coverover 13 years ago
The Best-Laid Plans...Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5